参麦注射液联合美托洛尔治疗扩张型心肌病患者的效果

Effects of Shenmai injection combined with Metoprolol in treatment of patients with dilated cardiomyopathy

目的:观察参麦注射液联合美托洛尔治疗扩张型心肌病患者的效果。方法:选取2020年12月至2022年12月该院收治的76例扩张型心肌病患者进行前瞻性研究,按照随机数字表法将其分为观察组和对照组各38例。对照组给予美托洛尔治疗,观察组在对照组基础上联合参麦注射液治疗,比较两组临床疗效,治疗前后心功能指标[左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)]水平,心肌损伤标志物[血清中心脏型肌球蛋白结合蛋白-C(cMyBP-C)、血浆肌钙蛋白I(cTnI)、血清骨膜蛋白(POSTN)、血清氨基末端脑利钠肽前体(NT-proBNP)]水平,以及不良反应发生率。结果:观察组治疗总有效率为94.74%,高于对照组的71.05%,差异有统计学意义(P<0.05);治疗后,两组LVEF水平均高于治疗前,且观察组高于对照组,两组LVESD、LVEDD水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组cMyBP-C、cTnI、POSTN和NT-proBNP水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:参麦注射液联合美托洛尔治疗扩张型心肌病患者,可提高临床疗效,改善心功能,减轻心肌损伤,效果优于单纯美托洛尔治疗。

Objective:To observe effects of Shenmai injection combined with Metoprolol in treatment of patients with dilated cardiomyopathy.Methods:A prospective study was conducted on 76 patients with dilated cardiomyopathy admitted to this hospital from December 2020 to December 2022.They were divided into observation group and control group according to the random number table method,38 cases in each.The control group was treated with Metoprolol,while the observation group was treated with Shenmai injection on the basis of that of the control group.The clinical efficacy,the cardiac function index levels[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)]levels before and after the treatment,the myocardial injury marker levels[serum cardiac myosin binding protein-C(cMyBP-C),plasma troponin I(cTnI),serum periostin(POSTN),serum N-terminal pro brain natriuretic peptide(NT-proBNP)],and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 94.74%,which was higher than 71.05%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the LVEF levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the levels of LVESD and LVEDD in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).The levels of cMyBP-C,cTnI,POSTN and NT-proBNP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Shenmai injection combined with Metoprolol in the treatment of the patients with dilated cardiomyopathy can improve the clinical efficacy,improve the cardiac function and reduce the myocardial injury.Moreover,it is superior to single Metoprolol treatment.